MX2010003325A - Anticuepos novedosos. - Google Patents

Anticuepos novedosos.

Info

Publication number
MX2010003325A
MX2010003325A MX2010003325A MX2010003325A MX2010003325A MX 2010003325 A MX2010003325 A MX 2010003325A MX 2010003325 A MX2010003325 A MX 2010003325A MX 2010003325 A MX2010003325 A MX 2010003325A MX 2010003325 A MX2010003325 A MX 2010003325A
Authority
MX
Mexico
Prior art keywords
novel antibodies
relates
present
novel anti
antibodies
Prior art date
Application number
MX2010003325A
Other languages
English (en)
Inventor
Weilan Ye
Yan Wu
Wei-Ching Liang
Gregory D Plowman
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MX2010003325A publication Critical patent/MX2010003325A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

La presente invenci?n se refiere al uso de antagonistas del VEGF y un novedoso anticuerpo anti-a5?1 para el tratamiento de c?ncer y la inhibici?n de la angiog?nesis y/o la permeabilidad vascular, incluso en la angiog?nesis anormal en enfermedades. La presente invenci?n tambi?n se relaciona con las composiciones y kits que comprenden los anticuerpos novedosos anti-a5?1 y los m?todos para desarrollarlos o utilizarlos.
MX2010003325A 2007-09-26 2008-09-25 Anticuepos novedosos. MX2010003325A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97547107P 2007-09-26 2007-09-26
PCT/US2008/077622 WO2009042746A1 (en) 2007-09-26 2008-09-25 Novel antibodies

Publications (1)

Publication Number Publication Date
MX2010003325A true MX2010003325A (es) 2010-04-09

Family

ID=40329277

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010003325A MX2010003325A (es) 2007-09-26 2008-09-25 Anticuepos novedosos.

Country Status (22)

Country Link
US (3) US7973138B2 (es)
EP (1) EP2200700B1 (es)
JP (1) JP2011501656A (es)
KR (1) KR20100065162A (es)
CN (1) CN101888878B (es)
AR (1) AR066170A1 (es)
AU (1) AU2008304452B2 (es)
BR (1) BRPI0816049A2 (es)
CA (1) CA2698609A1 (es)
CL (1) CL2008002856A1 (es)
CO (1) CO6260094A2 (es)
DK (1) DK2200700T3 (es)
HR (1) HRP20160308T1 (es)
HU (1) HUE027911T2 (es)
MX (1) MX2010003325A (es)
MY (1) MY151191A (es)
NZ (1) NZ584838A (es)
PE (1) PE20091029A1 (es)
RU (1) RU2490277C2 (es)
SI (1) SI2200700T1 (es)
TW (1) TWI547503B (es)
WO (1) WO2009042746A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100065162A (ko) 2007-09-26 2010-06-15 제넨테크, 인크. 신규한 항체
NZ594343A (en) 2009-03-25 2013-10-25 Genentech Inc Novel anti-alpha5beta1 antibodies and uses thereof
CA2665956A1 (en) * 2009-05-07 2010-11-07 Samir Patel Combination treatment for ocular diseases
WO2010129904A1 (en) 2009-05-08 2010-11-11 Genentech, Inc. Humanized anti-egfl7 antibodies and methods using same
US8956600B2 (en) 2009-08-10 2015-02-17 Taiwan Liposome Co. Ltd. Ophthalmic drug delivery system containing phospholipid and cholesterol
US8852592B2 (en) 2011-05-10 2014-10-07 Biocare Medical, Llc Systems and methods for anti-PAX8 antibodies
US20130058926A1 (en) * 2011-08-30 2013-03-07 Shiseido Company, Ltd. Method for alleviating and/or preventing skin reddening
US10316103B1 (en) 2012-03-30 2019-06-11 Biocare Medical, Llc Systems and methods for anti-Uroplakin III antibodies
US9494597B2 (en) * 2012-04-02 2016-11-15 Ab Biosciences, Inc. Human control antibodies and uses therefor
DK2847231T3 (da) 2012-05-10 2019-10-14 Bioatla Llc Multispecifikke monoklonale antistoffer
JP6324970B2 (ja) 2012-09-27 2018-05-23 バイオケア メディカル， エルエルシー 抗ウロプラキンｉｉ抗体システムおよび方法
WO2014100220A2 (en) 2012-12-18 2014-06-26 Biocare Medical, Llc Antibody cocktail systems and methods for classification of histologic subtypes in lung cancer
RU2681994C2 (ru) * 2012-12-26 2019-03-14 Онкосинерджи, Инк. КОМПОЗИЦИИ АНТИТЕЛА К ИНТЕГРИНУ β1 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
WO2014114298A1 (en) 2013-01-23 2014-07-31 Syddansk Universitet Mfap4 binding antibodies blocking the interaction between mfap4 and integrin receptors
EP3620468A1 (en) * 2013-02-05 2020-03-11 EngMab Sàrl Method for the selection of antibodies against bcma
EP2962113B1 (en) 2013-02-28 2019-04-03 Biocare Medical, LLC Anti-p40 antibodies systems and methods
WO2015051320A2 (en) 2013-10-03 2015-04-09 Biocare Medical, Llc Anti-sox10 antibody systems and methods
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
RU2744860C2 (ru) 2015-12-30 2021-03-16 Кодиак Сайенсиз Инк. Антитела и их конъюгаты
CN108693004B (zh) * 2018-05-24 2020-08-04 中国农业科学院农业质量标准与检测技术研究所 一种检测菜籽粕中是否掺杂抗生素滤渣的方法
WO2020205849A1 (en) * 2019-04-01 2020-10-08 Lakepharma, Inc. Btla-binding (cd272) antibodies for modulating immune response and treating disease
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
CN114688461A (zh) * 2020-12-31 2022-07-01 青岛海尔施特劳斯水设备有限公司 一种漏水检测方法及***
CN113133431A (zh) * 2021-02-25 2021-07-20 中南大学 慢性高眼压合并长眼轴动物模型的建立方法、模型及应用
CN114073996B (zh) * 2021-11-24 2023-04-14 中山大学 一种嵌套式微井阵列芯片及其制备方法

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5540933A (en) 1985-05-31 1996-07-30 La Jolla Cancer Research Foundation Isolation and use of fibronectin receptor
EP0330506A3 (en) 1988-02-26 1990-06-20 Dana Farber Cancer Institute Vla proteins
US20020146410A1 (en) 1992-05-22 2002-10-10 Helmut Eckert Monoclonal antibodies and their use
US5981478A (en) * 1993-11-24 1999-11-09 La Jolla Cancer Research Foundation Integrin-binding peptides
US5627263A (en) 1993-11-24 1997-05-06 La Jolla Cancer Research Foundation Integrin-binding peptides
DK0719859T3 (da) 1994-12-20 2003-10-20 Merck Patent Gmbh Anti-alfa V-integrin monoklonalt antistof
EP1049718B1 (en) 1998-01-23 2006-04-05 MERCK PATENT GmbH Use of the antibody 271.14d9.f8 (dsm acc2331) to inhibit in vitro alphavbeta6-integrin attachment to fibronectin
US6852318B1 (en) * 1998-05-08 2005-02-08 The Regents Of The University Of California Methods for detecting and inhibiting angiogenesis
EP2327451B1 (en) 1998-05-08 2013-10-23 The Regents of the University of California Method for detecting and inhibiting angiogenesis
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
GB9909392D0 (en) 1999-04-24 1999-06-23 Imp Cancer Res Tech Treatment, imaging and diagnosis of disease
MXPA02001439A (es) 1999-08-11 2002-08-30 Eos Biotechnology Inc Nuevos metodos para el diagnostico de angiogenesis, composiciones y metodos de exhibicion de moduladores de la angiogenesis.
US20040009494A1 (en) 1999-08-11 2004-01-15 Richard Murray Novel methods of diagnosis of angiogenesis and other conditions, compositions, and the methods of screening for modulators
US20030152926A1 (en) 1999-08-11 2003-08-14 Eos Biotechnology, Inc. Novel methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators
US20020015970A1 (en) 1999-08-11 2002-02-07 Richard Murray Novel methods of diagnosis of angiogenesis, compositions, and methods of screening for angiogenesis modulators
US20020019330A1 (en) 1999-08-11 2002-02-14 Richard Murray Novel methods of diagnosis of angiogenesis, compositions, and methods of screening for angiogenesis modulators
US20040259152A1 (en) 2000-02-22 2004-12-23 Richard Murray Novel methods of diagnosing and screening for modulators of tissue remodeling and treating related diseases
JP2004531249A (ja) 2001-02-14 2004-10-14 プロテイン デザイン ラブス インコーポレイティド 血管新生の診断方法、組成物、及び血管新生モジュレータのスクリーニング方法
WO2002086443A2 (en) 2001-04-18 2002-10-31 Protein Design Labs, Inc Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer
AU2002314901A1 (en) 2001-06-04 2002-12-16 Eos Biotechnology, Inc. Methods of diagnosis and treatment of androgen-dependent prostate cancer, prostate cancer undergoing androgen-withdrawal, and androgen-independent prostate cancer
EP1517998A2 (en) 2001-06-18 2005-03-30 EOS Biotechnology, Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
US7189507B2 (en) 2001-06-18 2007-03-13 Pdl Biopharma, Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
US20040076955A1 (en) 2001-07-03 2004-04-22 Eos Biotechnology, Inc. Methods of diagnosis of bladder cancer, compositions and methods of screening for modulators of bladder cancer
US20040033495A1 (en) 2001-08-03 2004-02-19 Eos Biotechnology, Inc. Methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators
US20030124579A1 (en) 2001-09-05 2003-07-03 Eos Biotechnology, Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
JP2005518782A (ja) 2001-09-17 2005-06-30 プロテイン デザイン ラブス， インコーポレイテッド ガンの診断方法、ガンのモジュレータのスクリーニング組成物及び方法
US20070042360A1 (en) 2001-09-17 2007-02-22 Eos Biotechnology, Inc. Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
US20030232350A1 (en) 2001-11-13 2003-12-18 Eos Biotechnology, Inc. Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
WO2003042661A2 (en) 2001-11-13 2003-05-22 Protein Design Labs, Inc. Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
US20060241067A1 (en) 2002-06-25 2006-10-26 Varner Judith A Methods For inhibiting angiogenesis, cell migration, cell adhesion, and cell survival
EP1539247A4 (en) 2002-07-16 2007-08-29 Univ New Jersey Med ALPHA 5 BETA 1 AND ITS ABILITY TO REGULATE THE CELL SURVIVAL PATH
US7276589B2 (en) * 2002-11-26 2007-10-02 Pdl Biopharma, Inc. Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis
US7285268B2 (en) * 2002-11-26 2007-10-23 Pdl Biopharma, Inc. Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis
WO2004048938A2 (en) 2002-11-26 2004-06-10 Protein Design Labs, Inc. Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators
JP4741242B2 (ja) * 2002-11-26 2011-08-03 アボット バイオセラピューティクス コーポレイション 新脈管形成を調節するα５β１インテグリンへのキメラ及びヒト化抗体
US20050002930A1 (en) 2003-04-03 2005-01-06 Johnson Dale E. Methods of production and use of anti-integrin antibodies for the control of tissue granulation
JP4857259B2 (ja) * 2004-03-24 2012-01-18 アボット バイオセラピューティクス コーポレイション 癌細胞増殖を阻害するための抗α５β１抗体の使用
US20060008415A1 (en) 2004-06-25 2006-01-12 Protein Design Labs, Inc. Stable liquid and lyophilized formulation of proteins
PL1819359T3 (pl) 2004-12-09 2015-08-31 Janssen Biotech Inc Immunokoniugaty skierowane przeciw integrynie, metody ich wytwarzania oraz ich zastosowanie
EP2091916A2 (en) 2005-11-23 2009-08-26 AstraZeneca AB L-phenylalanine derivatives and their use as integrin antagonists
US20090111828A1 (en) 2005-11-23 2009-04-30 Astrazeneca Ab L-alanine derivatives
JP2009526032A (ja) 2006-02-09 2009-07-16 アストラゼネカ アクチボラグ 化合物
WO2008060645A2 (en) * 2006-03-21 2008-05-22 Genentech, Inc. Combinatorial therapy involving alpha5beta1 antagonists
AU2007253586A1 (en) 2006-05-24 2007-11-29 Bayer Schering Pharma Aktiengesellschaft High affinity human and humanized anti-alpha5beta1 integrin function blocking antibodies with reduced immunogenicity
KR20100065162A (ko) 2007-09-26 2010-06-15 제넨테크, 인크. 신규한 항체
US8039596B2 (en) 2008-02-05 2011-10-18 Bristol-Myers Squibb Company Alpha 5-beta 1 antibodies and their uses

Also Published As

Publication number Publication date
MY151191A (en) 2014-04-30
AR066170A1 (es) 2009-07-29
TWI547503B (zh) 2016-09-01
CL2008002856A1 (es) 2009-01-16
AU2008304452A1 (en) 2009-04-02
RU2490277C2 (ru) 2013-08-20
NZ584838A (en) 2012-08-31
TW200924794A (en) 2009-06-16
RU2010116184A (ru) 2011-11-10
EP2200700A1 (en) 2010-06-30
CO6260094A2 (es) 2011-03-22
WO2009042746A1 (en) 2009-04-02
US20120156129A1 (en) 2012-06-21
BRPI0816049A2 (pt) 2019-09-24
HUE027911T2 (en) 2016-11-28
HRP20160308T1 (hr) 2016-04-22
EP2200700B1 (en) 2016-01-13
US20090098112A1 (en) 2009-04-16
JP2011501656A (ja) 2011-01-13
PE20091029A1 (es) 2009-08-19
US9284376B2 (en) 2016-03-15
SI2200700T1 (sl) 2016-04-29
CN101888878A (zh) 2010-11-17
CA2698609A1 (en) 2009-04-02
KR20100065162A (ko) 2010-06-15
AU2008304452B2 (en) 2014-01-16
CN101888878B (zh) 2014-05-21
US20120148572A1 (en) 2012-06-14
US8840887B2 (en) 2014-09-23
US7973138B2 (en) 2011-07-05
DK2200700T3 (en) 2016-04-11

Similar Documents

Publication Publication Date Title
MY151191A (en) Novel antibodies
MY159375A (en) Combinatorial therapy
PH12015500248A1 (en) Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
ATE469895T1 (de) Cgrp-rezeptorantagonisten
MX2009008104A (es) Hepcidina, antagonistas de hepcidina y metodos de uso.
MX2009004532A (es) Composiciones y metodos para unir esfingosina-1-fosfato.
TW200709817A (en) Platform antibody compositions
MY152068A (en) Bispecific anti-her antibodies
UA101478C2 (ru) Соединения, полезные как ингибиторы raf-киназы
SG10201405377XA (en) Compositions and methods for antibodies targeting complement protein c5
EA201001639A1 (ru) Композиции и способы их получения и применения
TW200714290A (en) Anti-M-CSF antibody compositions having reduced levels of endotoxin
TN2011000528A1 (en) Compositions and methods for antibodies targeting complement protein c3b
EP2582722A4 (en) ANTIBODIES AGAINST GD2
MY161909A (en) Anti-her3 antibodies and uses thereof
MX353706B (es) Anticuerpos contra csf-1r humano y usos de los mismos.
MXPA06014510A (es) Composiciones y metodos para tratar trastornos inflamatorios.
MX2009012625A (es) Metodos para el tratamiento, diagnostico y deteccion de trastornos asociados con el fgf21.
JO2576B1 (en) Antibodies
MX2011001679A (es) Derivados de flavina.
TW200621714A (en) Novel anthranilamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors
MX2010003013A (es) Inhibicion de angiogenesis.
TNSN08370A1 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
TW200621244A (en) Modulators of muscarinic receptors
EP2101772A4 (en) NEUROMUSCULAR BLOCKAGE AGENTS WITH INTERMEDIATE DURATION AND THEIR ANTAGONISTS

Legal Events

Date Code Title Description
FG Grant or registration